These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 30975125)

  • 21. PIK3CA hotspot mutations differentially impact responses to MET targeting in MET-driven and non-driven preclinical cancer models.
    Nisa L; Häfliger P; Poliaková M; Giger R; Francica P; Aebersold DM; Charles RP; Zimmer Y; Medová M
    Mol Cancer; 2017 May; 16(1):93. PubMed ID: 28532501
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SGK3 mediates INPP4B-dependent PI3K signaling in breast cancer.
    Gasser JA; Inuzuka H; Lau AW; Wei W; Beroukhim R; Toker A
    Mol Cell; 2014 Nov; 56(4):595-607. PubMed ID: 25458846
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MicroRNA-144-3p suppresses tumor growth and angiogenesis by targeting SGK3 in hepatocellular carcinoma.
    Wu M; Huang C; Huang X; Liang R; Feng Y; Luo X
    Oncol Rep; 2017 Oct; 38(4):2173-2181. PubMed ID: 28849156
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Down-regulation of LncRNA NR027113 inhibits cell proliferation and metastasis via PTEN/PI3K/AKT signaling pathway in hepatocellular carcinoma.
    Chen Z; Zhou ZY; He CC; Zhang JL; Wang J; Xiao ZY
    Eur Rev Med Pharmacol Sci; 2018 Nov; 22(21):7222-7232. PubMed ID: 30468465
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mutationally activated PIK3CA(H1047R) cooperates with BRAF(V600E) to promote lung cancer progression.
    Trejo CL; Green S; Marsh V; Collisson EA; Iezza G; Phillips WA; McMahon M
    Cancer Res; 2013 Nov; 73(21):6448-61. PubMed ID: 24019382
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mechanism of activation of SGK3 by growth factors via the Class 1 and Class 3 PI3Ks.
    Malik N; Macartney T; Hornberger A; Anderson KE; Tovell H; Prescott AR; Alessi DR
    Biochem J; 2018 Jan; 475(1):117-135. PubMed ID: 29150437
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PIK3CA mutations-mediated downregulation of circLHFPL2 inhibits colorectal cancer progression via upregulating PTEN.
    Chong X; Chen J; Zheng N; Zhou Z; Hai Y; Chen S; Zhang Y; Yu Q; Yu S; Chen Z; Bao W; Quan M; Chen ZS; Zhan Y; Gao Y
    Mol Cancer; 2022 May; 21(1):118. PubMed ID: 35619132
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Co-activation of PIK3CA and Yap promotes development of hepatocellular and cholangiocellular tumors in mouse and human liver.
    Li X; Tao J; Cigliano A; Sini M; Calderaro J; Azoulay D; Wang C; Liu Y; Jiang L; Evert K; Demartis MI; Ribback S; Utpatel K; Dombrowski F; Evert M; Calvisi DF; Chen X
    Oncotarget; 2015 Apr; 6(12):10102-15. PubMed ID: 25826091
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The PIK3CA E542K and E545K mutations promote glycolysis and proliferation via induction of the β-catenin/SIRT3 signaling pathway in cervical cancer.
    Jiang W; He T; Liu S; Zheng Y; Xiang L; Pei X; Wang Z; Yang H
    J Hematol Oncol; 2018 Dec; 11(1):139. PubMed ID: 30547809
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of PIK3CA mutant E545K in the mammary gland induces heterogeneous tumors but is less potent than mutant H1047R.
    Meyer DS; Koren S; Leroy C; Brinkhaus H; Müller U; Klebba I; Müller M; Cardiff RD; Bentires-Alj M
    Oncogenesis; 2013 Sep; 2(9):e74. PubMed ID: 24080956
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Membrane metallo-endopeptidase mediates cellular senescence induced by oncogenic PIK3CA
    Liu XL; Liu JL; Xu YC; Zhang X; Wang YX; Qing LH; Guo W; Ding J; Meng LH
    Int J Cancer; 2019 Aug; 145(3):817-829. PubMed ID: 30671946
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The E545K mutation of PIK3CA promotes gallbladder carcinoma progression through enhanced binding to EGFR.
    Zhao S; Cao Y; Liu SB; Wang XA; Bao RF; Shu YJ; Hu YP; Zhang YJ; Jiang L; Zhang F; Liang HB; Li HF; Ma Q; Xu Y; Wang Z; Zhang YC; Chen L; Zhou J; Liu YB
    J Exp Clin Cancer Res; 2016 Jun; 35(1):97. PubMed ID: 27317099
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ΔNp63α is a common inhibitory target in oncogenic PI3K/Ras/Her2-induced cell motility and tumor metastasis.
    Hu L; Liang S; Chen H; Lv T; Wu J; Chen D; Wu M; Sun S; Zhang H; You H; Ji H; Zhang Y; Bergholz J; Xiao ZJ
    Proc Natl Acad Sci U S A; 2017 May; 114(20):E3964-E3973. PubMed ID: 28468801
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of
    Pearson HB; Li J; Meniel VS; Fennell CM; Waring P; Montgomery KG; Rebello RJ; Macpherson AA; Koushyar S; Furic L; Cullinane C; Clarkson RW; Smalley MJ; Simpson KJ; Phesse TJ; Shepherd PR; Humbert PO; Sansom OJ; Phillips WA
    Cancer Discov; 2018 Jun; 8(6):764-779. PubMed ID: 29581176
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phosphatidyl inositol-3 kinase (PIK3CA) E545K mutation confers cisplatin resistance and a migratory phenotype in cervical cancer cells.
    Arjumand W; Merry CD; Wang C; Saba E; McIntyre JB; Fang S; Kornaga E; Ghatage P; Doll CM; Lees-Miller SP
    Oncotarget; 2016 Dec; 7(50):82424-82439. PubMed ID: 27489350
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MicroRNA-203 suppresses proliferation in liver cancer associated with PIK3CA, p38 MAPK, c-Jun, and GSK3 signaling.
    Zhang A; Lakshmanan J; Motameni A; Harbrecht BG
    Mol Cell Biochem; 2018 Apr; 441(1-2):89-98. PubMed ID: 28887744
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design and Characterization of SGK3-PROTAC1, an Isoform Specific SGK3 Kinase PROTAC Degrader.
    Tovell H; Testa A; Zhou H; Shpiro N; Crafter C; Ciulli A; Alessi DR
    ACS Chem Biol; 2019 Sep; 14(9):2024-2034. PubMed ID: 31461270
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast Cancer.
    Loibl S; Darb-Esfahani S; Huober J; Klimowicz A; Furlanetto J; Lederer B; Hartmann A; Eidtmann H; Pfitzner B; Fasching PA; Tiemann K; Jackisch C; Mehta K; von Minckwitz G; Untch M; Denkert C
    Clin Cancer Res; 2016 Jun; 22(11):2675-83. PubMed ID: 26758558
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long Noncoding RNA lncARSR Promotes Doxorubicin Resistance in Hepatocellular Carcinoma via Modulating PTEN-PI3K/Akt Pathway.
    Li Y; Ye Y; Feng B; Qi Y
    J Cell Biochem; 2017 Dec; 118(12):4498-4507. PubMed ID: 28464252
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PIK3CA(H1047R)- and Her2-initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling.
    Cheng H; Liu P; Ohlson C; Xu E; Symonds L; Isabella A; Muller WJ; Lin NU; Krop IE; Roberts TM; Winer EP; Arteaga CL; Zhao JJ
    Oncogene; 2016 Jun; 35(23):2961-70. PubMed ID: 26640141
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.